ERBA Diagnostics, Inc. Appoints Mohan Gopalkrishnan V.P. Operations

Thu Feb 7, 2013 8:20am EST

* Reuters is not responsible for the content in this press release.

--Experienced in U.S. and Global Medical Diagnostics, Healthcare and
MIAMI--(Business Wire)--
ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics
company, has appointed Mohan Gopalkrishnan as Vice President - Operations. Mr.
Gopalkrishnan will be responsible for managing ERBA Diagnostics` daily
operations and will be based in its Miami headquarters. 

Kevin Clark, President and Chief Executive Officer of ERBA Diagnostics, said,
"Mohan Gopalkrishnan`s appointment as V.P. Operations is a welcome strengthening
of our management team. With a lifelong career in the healthcare industry, we
expect that Mohan`s experience will strengthen the management team and improve
efficiencies to help the company reach its full potential." 

Mr. Gopalkrishnan, age 57, has over 30 years of experience in the diagnostics
and medical devices industry. He started his career with Boehringer Mannheim in
India and spent the last 15 years with Becton Dickinson, starting as a Business
Leader for Medical Devices in India and then as ERP Leader for Asia and Business
Director for Asia based in Singapore and, during the most recent five years, in
the U.S. as Senior Director with global responsibility for a $550 million

Mr. Clark continued, "Mohan Gopalkrishnan has demonstrated that he is an
experienced business leader with a consistent track record of building
sustainable businesses across countries, regions and global platforms with
strong strategic capabilities balanced with intense execution focus to drive
growth through customer centric product and services innovation. We are
confident that Mohan will be a catalyst of change for driving and sustaining
growth and developing talent within our organization." 

About ERBA Diagnostics, Inc.

ERBA Diagnostics, Inc. (, headquartered in Miami,
Florida, is a fully integrated in vitro diagnostics company that develops,
manufactures and distributes in the United States and internationally,
proprietary diagnostic reagents, test kits and instrumentation, primarily for
autoimmune and infectious diseases, through its legacy subsidiaries - Diamedix
Corporation (U.S.), Delta Biologicals S.r.l. (Europe) and ImmunoVision, Inc.
(U.S.) - and through its recently acquired subsidiaries - Drew Scientific, Inc.
(U.S.), JAS Diagnostics, Inc. (U.S.) and Drew Scientific Limited Co. (Europe). 

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press
release are forward-looking and are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995.Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect
the business and prospects of ERBA Diagnostics, Inc., including, without
limitation:the risks and uncertainties associated with ERBA Diagnostics`
business strategies, including, without limitation, the risk Mr. Gopalkrishnan`s
appointment may not be a catalyst for change, may not have a positive impact on
its success or that such business strategies may not otherwise be successful or
lead to ERBA Diagnostics achieving improved efficiencies, sales or operating
results; the risk that ERBA Diagnostics may not be able to achieve its goals or
grow, develop or sustain its business; and other risks and uncertainties that
may cause results to differ materially from those set forth in the
forward-looking statements.In addition to the risks and uncertainties set forth
above, investors should consider the economic, competitive, governmental,
technological and other risks and uncertainties discussed in ERBA Diagnostics`
filings with the Securities and Exchange Commission, including, without
limitation, the risks and uncertainties discussed under the heading "Risk
Factors" in such filings.

ERBA Diagnostics, Inc.
Kevin Clark, 305-324-2300
CEO, COO and President

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.